Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Dec 11, 2024 6:28pm
51 Views
Post# 36357808

RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsBig Pharma M&A activities were "cooled" in 2024, particularly because of the FTC's restrictive actions on companies that were looking towards vertically focused M&A activities that would otherwise have bolstered their oncology pipelines through the integration of new products that were aligned with their pipeline's objectives. The largest deal announced by far was Novo Holdings’ proposed $16.5 billion buyout of contract development and manufacturing organization (CDMO) Catalent. Outside of that, the leading pharmaceutical companies all found something in a buffet of sub-$5 billion deals primarily in immunology ex. oncology. Part of the reason for the sub-US$5 Billion deals is that smaller biotechs are increasingly opting to take their drug to market on their own. Anothr reason is that there are few late-stage options for Big Pharma to purchase.

So in 2024 Big Pharma moved further upstream in the clinical development continuum to acquire earlier stage companies, with lower value assets that target lower calue targets, like those in immunology targeting chronic respiratory indications.

The acquisition of early-stage stage companies not only resulted in lower value deal-making in 2024 but also precluded Big Pharma having to face the wrath of the FTC. 

With the US election now n the rear-view mirror, Big Pharma appears ready to ramp-up its M&A deal-making activity in 2025. The preface to this increase in M&A activity happens to because Big Pharma doesn't foresee FTC interference on the closing of big valution deals involving vertically integrated product pipelines AND Big Pharma is facing a looming patent cliff on some of its largest value "blockbuster products".

Oncology still remains the biggest high-value target for Big Pharma's M&A and late-stage clinical development cancer companies with complementary drug products to Big Pharma's oncology pipelines, like ONCY's pelareorep platform, are viewed as
 those companies that will be acquired at significant 'buyout' premiums, as compared to those that don't posses those high-value targets or product pipeline synergies.
<< Previous
Bullboard Posts
Next >>